Does the media favor ABEO or SVRA?

In the previous week, Abeona Therapeutics had 6 more articles in the media than Savara. MarketBeat recorded 17 mentions for Abeona Therapeutics and 11 mentions for Savara. Savara's average media sentiment score of 0.93 beat Abeona Therapeutics' score of 0.51 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MLTX or ABEO?

In the previous week, Abeona Therapeutics had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 17 mentions for Abeona Therapeutics and 16 mentions for MoonLake Immunotherapeutics. Abeona Therapeutics' average media sentiment score of 0.51 beat MoonLake Immunotherapeutics' score of -0.15 indicating that Abeona Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Abeona Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABEO or IMTX?

In the previous week, Abeona Therapeutics had 9 more articles in the media than Immatics. MarketBeat recorded 17 mentions for Abeona Therapeutics and 8 mentions for Immatics. Abeona Therapeutics' average media sentiment score of 0.51 beat Immatics' score of -0.31 indicating that Abeona Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor ABEO or CGEM?

In the previous week, Abeona Therapeutics had 2 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 17 mentions for Abeona Therapeutics and 15 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.79 beat Abeona Therapeutics' score of 0.51 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ABEO or ORIC?

In the previous week, Abeona Therapeutics had 14 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 17 mentions for Abeona Therapeutics and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.63 beat Abeona Therapeutics' score of 0.51 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Abeona Therapeutics (ABEO) Competitors

$2.29 -0.01 (-0.43%)

Closing price 11/12/2026 04:00 PM Eastern

Extended Trading

$2.36 +0.07 (+3.23%)

As of 04:02 AM Eastern

Compare

ABEO vs. SVRA, MLTX, IMTX, CGEM, and ORIC

Should you buy Abeona Therapeutics stock or one of its competitors? Abeona Therapeutics's main competitors and comparable companies include Savara (SVRA), MoonLake Immunotherapeutics (MLTX), Immatics (IMTX), Cullinan Therapeutics (CGEM), and Oric Pharmaceuticals (ORIC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Abeona Therapeutics compare to Savara?

Abeona Therapeutics (NASDAQ:ABEO) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Abeona Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Savara has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Abeona Therapeutics has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	22.49	$71.18M	-$1.07	N/A
Savara	N/A	N/A	-$118.84M	-$0.61	N/A

In the previous week, Abeona Therapeutics had 6 more articles in the media than Savara. MarketBeat recorded 17 mentions for Abeona Therapeutics and 11 mentions for Savara. Savara's average media sentiment score of 0.93 beat Abeona Therapeutics' score of 0.51 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abeona Therapeutics currently has a consensus price target of $21.00, suggesting a potential upside of 817.03%. Savara has a consensus price target of $10.25, suggesting a potential upside of 117.16%. Given Abeona Therapeutics' higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Savara	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Savara has a net margin of 0.00% compared to Abeona Therapeutics' net margin of -160.30%. Abeona Therapeutics' return on equity of -44.82% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	-160.30%	-44.82%	-32.51%
Savara	N/A	-96.87%	-74.22%

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Abeona Therapeutics beats Savara on 8 of the 14 factors compared between the two stocks.

How does Abeona Therapeutics compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 7.1% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Abeona Therapeutics' net margin of -160.30%. Abeona Therapeutics' return on equity of -44.82% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-79.95%	-56.40%
Abeona Therapeutics	-160.30%	-44.82%	-32.51%

In the previous week, Abeona Therapeutics had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 17 mentions for Abeona Therapeutics and 16 mentions for MoonLake Immunotherapeutics. Abeona Therapeutics' average media sentiment score of 0.51 beat MoonLake Immunotherapeutics' score of -0.15 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abeona Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics currently has a consensus price target of $31.33, suggesting a potential upside of 143.46%. Abeona Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 817.03%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	2 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.60
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Abeona Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.67	N/A
Abeona Therapeutics	$5.82M	22.49	$71.18M	-$1.07	N/A

Summary

Abeona Therapeutics beats MoonLake Immunotherapeutics on 11 of the 15 factors compared between the two stocks.

How does Abeona Therapeutics compare to Immatics?

Abeona Therapeutics (NASDAQ:ABEO) and Immatics (NASDAQ:IMTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Abeona Therapeutics has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	22.49	$71.18M	-$1.07	N/A
Immatics	$54.60M	16.32	-$222.26M	-$1.95	N/A

In the previous week, Abeona Therapeutics had 9 more articles in the media than Immatics. MarketBeat recorded 17 mentions for Abeona Therapeutics and 8 mentions for Immatics. Abeona Therapeutics' average media sentiment score of 0.51 beat Immatics' score of -0.31 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immatics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Abeona Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Immatics has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Abeona Therapeutics has a net margin of -160.30% compared to Immatics' net margin of -533.26%. Abeona Therapeutics' return on equity of -44.82% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	-160.30%	-44.82%	-32.51%
Immatics	-533.26%	-52.27%	-43.99%

Abeona Therapeutics currently has a consensus price target of $21.00, indicating a potential upside of 817.03%. Immatics has a consensus price target of $19.00, indicating a potential upside of 191.41%. Given Abeona Therapeutics' higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Immatics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Abeona Therapeutics beats Immatics on 13 of the 16 factors compared between the two stocks.

How does Abeona Therapeutics compare to Cullinan Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

In the previous week, Abeona Therapeutics had 2 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 17 mentions for Abeona Therapeutics and 15 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.79 beat Abeona Therapeutics' score of 0.51 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abeona Therapeutics currently has a consensus price target of $21.00, indicating a potential upside of 817.03%. Cullinan Therapeutics has a consensus price target of $34.14, indicating a potential upside of 235.06%. Given Abeona Therapeutics' higher probable upside, research analysts plainly believe Abeona Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Abeona Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	22.49	$71.18M	-$1.07	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.07	N/A

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cullinan Therapeutics has a net margin of 0.00% compared to Abeona Therapeutics' net margin of -160.30%. Abeona Therapeutics' return on equity of -44.82% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	-160.30%	-44.82%	-32.51%
Cullinan Therapeutics	N/A	-59.06%	-52.93%

Abeona Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

Summary

Abeona Therapeutics beats Cullinan Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Abeona Therapeutics compare to Oric Pharmaceuticals?

Abeona Therapeutics (NASDAQ:ABEO) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Abeona Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	22.49	$71.18M	-$1.07	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

Oric Pharmaceuticals has a net margin of 0.00% compared to Abeona Therapeutics' net margin of -160.30%. Oric Pharmaceuticals' return on equity of -35.35% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	-160.30%	-44.82%	-32.51%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

In the previous week, Abeona Therapeutics had 14 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 17 mentions for Abeona Therapeutics and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.63 beat Abeona Therapeutics' score of 0.51 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Abeona Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Abeona Therapeutics presently has a consensus target price of $21.00, indicating a potential upside of 817.03%. Oric Pharmaceuticals has a consensus target price of $21.25, indicating a potential upside of 150.00%. Given Abeona Therapeutics' higher probable upside, equities analysts clearly believe Abeona Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Summary

Abeona Therapeutics beats Oric Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Abeona Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABEO vs. The Competition

Export

Metric	Abeona Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$131.44M	$4.18B	$7.91B	$12.24B
Dividend Yield	N/A	3.62%	2.46%	4.51%
P/E Ratio	-2.14	34.65	35.24	28.47
Price / Sales	22.49	17.10	8.93	6.02
Price / Cash	N/A	26.89	22.23	22.80
Price / Book	1.04	4.16	4.49	3.83
Net Income	$71.18M	-$22.78M	$3.51B	$390.69M
7 Day Performance	-45.08%	-1.63%	-0.75%	0.52%
1 Month Performance	-49.34%	-4.50%	-3.18%	-6.02%
1 Year Performance	-49.45%	-0.49%	1.11%	-5.24%

Abeona Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABEO Abeona Therapeutics	2.9061 of 5 stars	$2.29 -0.4%	$21.00 +817.0%	-53.7%	$131.44M	$5.82M	N/A	226	Earnings Report Analyst Downgrade
SVRA Savara	2.6436 of 5 stars	$4.73 -1.9%	$10.25 +116.7%	+14.6%	$1.03B	N/A	N/A	70	Earnings Report Analyst Forecast
MLTX MoonLake Immunotherapeutics	3.4592 of 5 stars	$11.47 -2.6%	$28.50 +148.5%	+0.8%	$1.00B	N/A	N/A	130	Trending News Analyst Forecast Analyst Revision
IMTX Immatics	3.202 of 5 stars	$7.06 -1.9%	$19.00 +169.1%	-38.9%	$984.17M	$41.70M	N/A	704	Earnings Report Upcoming Earnings
CGEM Cullinan Therapeutics	3.2856 of 5 stars	$14.93 -0.7%	$33.86 +126.8%	+22.0%	$967.26M	N/A	N/A	109	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABEO) was last updated on 11/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abeona Therapeutics (ABEO) Competitors

ABEO vs. SVRA, MLTX, IMTX, CGEM, and ORIC

How does Abeona Therapeutics compare to Savara?

Summary

How does Abeona Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Abeona Therapeutics compare to Immatics?

Summary

How does Abeona Therapeutics compare to Cullinan Therapeutics?

Summary

How does Abeona Therapeutics compare to Oric Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abeona Therapeutics (ABEO) Competitors

ABEO vs. SVRA, MLTX, IMTX, CGEM, and ORIC

How does Abeona Therapeutics compare to Savara?

Which has more volatility & risk, ABEO or SVRA?

Which has preferable earnings & valuation, ABEO or SVRA?

Does the media favor ABEO or SVRA?

Do analysts recommend ABEO or SVRA?

Is ABEO or SVRA more profitable?

Do institutionals & insiders hold more shares of ABEO or SVRA?

Summary

How does Abeona Therapeutics compare to MoonLake Immunotherapeutics?

Do institutionals and insiders believe in MLTX or ABEO?

Which has more volatility & risk, MLTX or ABEO?

Is MLTX or ABEO more profitable?

Does the media prefer MLTX or ABEO?

Do analysts prefer MLTX or ABEO?

Which has higher earnings and valuation, MLTX or ABEO?

Summary

How does Abeona Therapeutics compare to Immatics?

Do insiders and institutionals believe in ABEO or IMTX?

Which has stronger valuation & earnings, ABEO or IMTX?

Does the media refer more to ABEO or IMTX?

Which has more volatility & risk, ABEO or IMTX?

Is ABEO or IMTX more profitable?

Do analysts rate ABEO or IMTX?

Summary

How does Abeona Therapeutics compare to Cullinan Therapeutics?

Does the media favor ABEO or CGEM?

Do analysts recommend ABEO or CGEM?

Which has stronger earnings & valuation, ABEO or CGEM?

Do institutionals and insiders have more ownership in ABEO or CGEM?

Is ABEO or CGEM more profitable?

Which has more risk & volatility, ABEO or CGEM?

Summary

How does Abeona Therapeutics compare to Oric Pharmaceuticals?

Which has stronger earnings & valuation, ABEO or ORIC?

Is ABEO or ORIC more profitable?

Does the media favor ABEO or ORIC?

Do institutionals and insiders have more ownership in ABEO or ORIC?

Which has more risk & volatility, ABEO or ORIC?

Do analysts recommend ABEO or ORIC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools